We are developing a deep pipeline of innovative siRNAs based on our mRNAi GOLD™ platform for diseases with a genetic basis. The depth and versatility of our liver-targeting technology gives us the opportunity to address a wide range of conditions in virtually any therapeutic area. Our wholly owned pipeline is currently focused in three therapeutic areas of high unmet need: hematology, cardiovascular disease, and rare diseases.
Zerlasiran (SLN360)
Cardiovascular Disease
Divesiran
(SLN124)
Polycythemia Vera (PV)
Multiple Hematologic Conditions
SLN548
Complement Mediated
Multiple programs
Undisclosed
1Licensed to AstraZeneca with milestones and royalties as part of ongoing collaboration to discover, develop and commercialize siRNA therapeutics for cardiovascular, renal, metabolic and respiratory diseases using Silence’s mRNAi GOLD™ platform